Abbott announced today that its FreeStyle Libre 2 continuous glucose monitoring (CGM) system received expanded reimbursement coverage in France for all people using basal insulin as part of their diabetes management.
Previously, the FreeStyle Libre 2 was only covered in France for people with Type 1 and Type 2 diabetes who require intensive insulin therapy or multiple daily injections. The decision...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?